Chengjun Sui
Impact in
- Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Research top 5%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
Papers in
-
- Circular RNAs in diseases 7
- RNA modifications and cancer 5
-
- MicroRNA in disease regulation 12
- Cancer-related molecular mechanisms research 10
- Co-authors
- Yanming Zhou (14 shared papers)Jiamei Yang (19 shared papers)Weifeng Shen (12 shared papers)Jiamei Yang (13 shared papers)Jiongjiong Lu (10 shared papers)Binghua Dai (18 shared papers)Zhengfeng Yin (3 shared papers)Bin Li (5 shared papers)
- Journals
- Advanced Science (3 papers)Frontiers in Oncology (2 papers)Frontiers in Pharmacology (2 papers)World Journal of Surgical Oncology (2 papers)Cancer Letters (2 papers)
- Partner nations
- ChinaItalySouth Korea
In The Last Decade
Chengjun Sui
56 papers receiving 1.5k citations
Peers
Comparison fields: 5 of 73
- Hepatology 327
- Cancer Research 529
- Oncology 360
- Molecular Biology 597
- Surgery 313
Countries citing papers authored by Chengjun Sui
This map shows the geographic impact of Chengjun Sui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chengjun Sui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chengjun Sui more than expected).
Fields of papers citing papers by Chengjun Sui
This network shows the impact of papers produced by Chengjun Sui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chengjun Sui. The network helps show where Chengjun Sui may publish in the future.
Co-authors
The 25 scholars most cited alongside Chengjun Sui, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 57 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 103 | |
| 2 | 2010 | 97 | |
| 3 | 2009 | 90 | |
| 4 | 2016 | 85 | |
| 5 | 2020 | 83 | |
| 6 | 2012 | 81 | |
| 7 | 2011 | 75 | |
| 8 | 2014 | 59 | |
| 9 | 2011 | 59 | |
| 10 | 2015 | 53 | |
| 11 | 2012 | 46 | |
| 12 | 2020 | 44 | |
| 13 | 2022 | 37 | |
| 14 | 2019 | 35 | |
| 15 | 2011 | 34 | |
| 16 | 2018 | 31 | |
| 17 | 2015 | 31 | |
| 18 | MicroRNA-147 suppresses human hepatocellular carcinoma proliferation migration and chemosensitivity by inhibiting HOXC6. | 2016 | 29 |
| 19 | 2012 | 28 | |
| 20 | 2021 | 27 |
About Chengjun Sui
Chengjun Sui is a scholar working on Molecular Biology, Cancer Research, Hepatology, Surgery and Oncology, having authored 57 papers that have together received 1.6k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (13 papers), MicroRNA in disease regulation (12 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (10 papers), Cancer-related molecular mechanisms research (10 papers), Circular RNAs in diseases (7 papers), RNA modifications and cancer (5 papers), Pancreatic and Hepatic Oncology Research (4 papers) and Cancer Cells and Metastasis (3 papers). The work is most often cited by research in Hepatology (327 citations), Cancer Research (529 citations), Oncology (360 citations), Molecular Biology (597 citations) and Surgery (313 citations). Chengjun Sui has collaborated with scholars based in China, Italy and South Korea. Frequent co-authors include Yanming Zhou, Jiamei Yang, Weifeng Shen, Jiamei Yang, Jiongjiong Lu, Binghua Dai, Zhengfeng Yin, Bin Li, Geng Li and Shuangjia Wang. Their work appears in journals such as Advanced Science, Frontiers in Oncology, Frontiers in Pharmacology, World Journal of Surgical Oncology and Cancer Letters.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.